Triple-combination approved in China for COPD
23 December 2019 07:00 GMT AstraZeneca's triple-combination therapyapproved in China for patients with COPD First fixed-dose triple-combination therapy in apressurised metered-dose inhaler device in China Budesonide/glycopyrronium/formoterol fumarate is known asPT010 outside of China and as Breztri Aerosphere in Japan AstraZeneca today announced that budesonide/glycopyrronium/formoterol fumarate has been approved in China for the maintenance treatment of chronic obstructive pulmonary disease (COPD). This is the first approval by the National Medical Products